Preeclampsia Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

The preeclampsia market addresses the clinical need for early detection, monitoring, and treatment of preeclampsia, a hypertensive disorder affecting approximately 2-8% of pregnancies worldwide and a leading cause of maternal and fetal morbidity and mortality. Market definitions vary across reports: the broader combined market sits at roughly $0.75 billion in 2026, while the diagnostics-only segment alone is estimated at $1.15 billion and the drugs/therapeutics segment at roughly $337-1,520 million depending on scope. The modest CAGR of ~1.72% reflects a mature clinical landscape where incremental improvements in biomarker-based screening are expanding the addressable market.

• •Market valued at ~$724-737 million in 2024-2025, reaching approximately $0.75 billion in 2026.
• •Two major sub-segments: diagnostics (~$1.15B in 2026) and therapeutics (projected at $337M-$610M by 2035 depending on report scope).
• •Steady but slow growth at ~1.72% CAGR through 2036, characteristic of a relatively mature specialty clinical market.

Rising global maternal age at first pregnancy, increasing prevalence of pre-existing hypertension, obesity, and type 2 diabetes in women of reproductive age, and expanding access to prenatal screening programs in emerging economies collectively expand the patient pool. Technological advances in biomarker-based diagnostics, particularly sFlt-1/PlGF ratio testing, Doppler ultrasound, and proteomic screening panels, improve early detection and create demand for new assay platforms. Healthcare policy initiatives prioritizing maternal health outcomes and reducing preventable complications also stimulate investment in screening infrastructure.

• •Growing prevalence of comorbid conditions (hypertension, obesity, diabetes) among pregnant women increases preeclampsia incidence rates globally.
• •Adoption of biomarker-based early-detection tests (e.g., sFlt-1/PlGF, PAPP-A) shifts clinical practice toward earlier intervention.
• •Expanding prenatal screening programs in Asia-Pacific and Latin America widen the addressable patient population.

The market is segmented by product type, diagnostic tests (laboratory assays, point-of-care rapid tests, imaging-based screening), therapeutic interventions (antihypertensives, magnesium sulfate, corticosteroids), and monitoring devices, as well as by end user (hospitals, specialty clinics, diagnostic laboratories). North America dominates with the U.S. diagnostics market alone estimated at $427 million in 2025, driven by advanced healthcare infrastructure and high prenatal screening adoption. Europe represents the second-largest regional market, while Asia-Pacific is the fastest-growing region due to improving obstetric care access and rising awareness.

• •U.S. preeclampsia diagnostics market valued at $427 million in 2025, projected to reach ~$593 million by 2035.
• •Diagnostics segment expected to reach $5.8 billion by 2034 under one broad market definition, reflecting rapid assay and technology adoption.
• •Asia-Pacific emerging as the fastest-growing region driven by expanding prenatal care infrastructure and rising maternal health awareness.

Who are the notable companies in the industry?

The preeclampsia market operates as a moderately consolidated specialty healthcare segment, with integrated pharmaceutical and diagnostics firms competing alongside dedicated molecular diagnostics and women's health specialists. Production is concentrated among large integrated healthcare companies with established obstetric/maternal health portfolios and specialized diagnostics manufacturers focusing on immunoassay and biomarker platforms. Key technology routes include immunoassay-based laboratory tests (ELISA, chemiluminescence), lateral flow point-of-care rapid tests, and Doppler ultrasound imaging, each serving distinct clinical workflows from hospital labs to bedside screening. Manufacturing capacity is concentrated in North America and Western Europe, with growing assembly and distribution networks in Asia-Pacific to serve emerging-market demand.

• •Market structure is moderately consolidated, dominated by integrated healthcare and diagnostics firms with obstetric/maternal health product portfolios.
• •Primary technology routes include immunoassay-based laboratory diagnostics, point-of-care lateral flow tests, and Doppler ultrasound imaging platforms.
• •Manufacturing and R&D capacity is concentrated in North America and Western Europe, with Asia-Pacific increasingly serving as a distribution and emerging-market production hub.

What are the recent trends and outlook?

The convergence of artificial intelligence and machine learning with ultrasound and biomarker data is accelerating the development of predictive risk models capable of identifying preeclampsia earlier in pregnancy than current standard-of-care screening. Multiplex biomarker panels and non-invasive cell-free DNA-based approaches are advancing through clinical development, promising to reshape the diagnostic competitive dynamic over the 2026-2036 forecast horizon. Therapeutics development remains an area of higher growth potential, with drug market projections reaching $2.37 billion by 2030 at a double-digit CAGR, though these figures reflect broader antihypertensive and supportive-care categories rather than preeclampsia-specific pharmacological innovation alone.

• •AI-powered risk prediction models and multiplex biomarker panels are emerging as the next generation of preeclampsia screening tools.
• •Therapeutics/drug segment projected at double-digit growth (up to 11.8% CAGR), significantly outpacing the overall market.
• •Long-term outlook through 2036 remains positive but tempered by slow clinical adoption cycles and the need for prospective clinical validation of new diagnostic modalities.